Pharmaceutical companies strengthen medical collaboration amid rising respiratory disease burden

Pharmaceutical companies are increasingly reinforcing their role as a bridge between academia, clinical practice, and real-world application, contributing to the dissemination of the latest medical advances to the healthcare community and improving the quality of treatment in Vietnam.

Leveraging R&D capabilities to strengthen professional connectivity amid the rising burden of respiratory diseases

Air pollution has become one of the most serious public health challenges in Vietnam, as fine particulate matter can penetrate deep into the lungs and cardiovascular system, increasing the risk of conditions such as stroke, heart disease, lung cancer, COPD, and respiratory infections. According to the World Health Organization (WHO), air pollution causes millions of deaths globally each year; in Vietnam alone, it is estimated to be associated with at least 70,000 deaths annually.

Against the backdrop of a growing burden of respiratory diseases, the need to continuously update professional knowledge and enhance diagnostic and treatment capabilities has become more urgent than ever. This also explains why specialized scientific conferences are increasingly affirming their critical role in connecting academia, clinical practice, and industry, thereby improving treatment quality and translating medical advances into practice.

Held from March 20–21, 2026, the HCM City Respiratory Society Annual Congress 2026 (HRS 2026) is one of the leading events in the field of respiratory medicine in Vietnam, bringing together more than 500 in-person participants and over 1,500 online attendees. Under the theme “Pioneering Science and Technology in Modern Pulmology,” the congress provided a comprehensive overview of advancements in diagnosis and treatment, ranging from the application of artificial intelligence (AI) and molecular biology to updates on treatment guidelines such as GOLD 2026, severe asthma, and COPD.

Imexpharm accompanied the HCM City Respiratory Society Annual Congress 2026 (HRS 2026) held in Vung Tau from March 20–21, 2026. Photo: Imexpharm

At the congress, Imexpharm -one of Vietnam’s leading pharmaceutical companies in antibiotics and cough medications-reaffirmed its long-term commitment to improving the quality of treatment for respiratory diseases. At the same time, the company continues to strengthen its role as a bridge between research and clinical practice, helping bring scientific advancements closer to real-world treatment and enhancing patient care outcomes.

With a strategic orientation toward closely aligning research activities with the practical needs of the healthcare system, Imexpharm currently operates 12 EU-GMP-certified production lines while maintaining an annual investment of approximately 5% of its revenue in research and development. On average, the company sustains over 100 research projects each year and launches 10–20 new products, contributing to the expansion of treatment portfolios-particularly in respiratory therapies and next-generation antibiotics. Notably, Imexpharm is among the pioneers in producing critical active ingredients such as colistin in powder form for inhalation solutions, supporting healthcare facilities in infection control and the effective treatment of severe, drug-resistant infections.

Implementing ESG and advancing medical collaboration to improve community ear, nose, and throat health

Beyond environmental pollution, climate change is also increasing the frequency and severity of infectious and respiratory diseases, placing mounting pressure on healthcare systems. According to UNICEF, climate change represents a health crisis, contributing to more frequent and severe disease outbreaks, extreme weather events, and threatening access to clean water-particularly in vulnerable regions of Vietnam. By 2050, climate change impacts could cost Vietnam between USD 1–3 billion in healthcare expenses and up to USD 23 billion in productivity losses.

During the same period (March 20–22, 2026), the 42nd Annual Ear Nose Throat Scientific Conference held in Nha Trang city gathered nearly 700 experts and physicians from across the country. Under the theme “Updating Diagnosis - Treatment –-Ear, Nose and Throat Care,” the conference highlighted the latest advancements in diagnosis, treatment, and the application of modern technologies such as artificial intelligence, immunology, and advanced surgical techniques. By accompanying the program, Imexpharm created opportunities to directly connect with the medical community and share treatment solutions aligned with real-world needs.

Imexpharm accompanied The 42nd Annual Scientific Conference on Ear, Nose and Throat held in Nha Trang from March 20–22, 2026. Photo: Imexpharm

High-quality pharmaceutical supply remains essential in reducing disease burden. The launch of a first generic antibiotic produced on EU-GMP-certified lines in late 2025 marked a major step forward for local pharma, improving access to affordable, high-quality treatments.

Imexpharm’s antibiotic portfolio covers key therapeutic groups, focusing on guideline-recommended and new-generation active ingredients. The company applies enzymatic technology to enhance purity and safety, reinforcing its leadership in ESG-driven manufacturing.
Aligned with international ESG standards, Imexpharm promotes sustainable growth through green, EU-GMP and WHO-GMP-compliant production. Its operations ensure strict quality control, energy efficiency, and effective waste management.

In March 2026, Imexpharm also launched the” Ngàn cây Mai Anh Đào - Vì một Đà Lạt mãi hồng (A Thousand Cherry Blossom Trees - For a Blooming Da Lat)” initiative, contributing to a cleaner environment and supporting respiratory health in the community.